Letter from the CEO
I trust that you have had a good summer. We have certainly been keeping busy here in Sweden during Q3 and expect to spend more time in the market now that US restrictions are being relaxed. Not only are we in the US reimbursement coverage process, but we’ve also welcomed specialist investor Van Herk. I think this is a good opportunity to provide a short update on recent events in SciBase, now that everything slowly starts to return to normal. First, let us do a short recap on what we have recently achieved.Important milestones during 2020… · FDA Approval – Opening up the US market